Search
Jefferies London: Terns' CEO Amy Burroughs previews the company's upcoming ASH presentation for the allosteric BCR::ABL1 inhibitor tern-701 in relapsed/refractory cml
The data has been accepted for an oral presentation on Monday, December 8 and will be followed by a company webcast with more info. Coverage brought to you by
3 hours ago
London Healthcare Week: After announcing FIH data from its oral GLP in obesity in September, Terns is also getting ready to release initial data in December for its allosteric BCR ABL cancer program
CEO Amy Burroughs walks us through what the company saw in the obesity program, and previews what to expect from initial cohorts in CML...
Nov 21, 2024
.png){kind=logo}
